What is virotherapy in cancer?
(VY-roh-THAYR-uh-pee) Treatment using a virus that has been changed in the laboratory to find and destroy cancer cells without harming healthy cells. It is a type of targeted therapy. Also called oncolytic virotherapy, oncolytic virus therapy, and viral therapy.
What cancers can oncolytic viruses treat?
To date, only one oncolytic virus—a genetically modified form of a herpesvirus for treating melanoma—has been approved by the Food and Drug Administration (FDA), though a number of viruses are being evaluated as potential treatments for cancer in clinical trials.
Which oncolytic immunotherapy is approved for metastatic melanoma?
The U.S. Food and Drug Administration has approved the use of Imlygic (talimogene laherparevec, also known as T-VEC) for the treatment of patients with melanoma lesions in the skin and lymph nodes. This approval is the FDA’s first for an oncolytic virus therapy.
What is an oncolytic agent?
An oncolytic virus is a virus that preferentially infects and kills cancer cells. As the infected cancer cells are destroyed by oncolysis, they release new infectious virus particles or virions to help destroy the remaining tumour.
Can oncolytic virus cause cancer?
After infection, these oncolytic viruses can cause cancer cells to “burst”—killing the cancer cells and releasing cancer antigens. These antigens can then stimulate immune responses that can seek out and eliminate any remaining tumor cells nearby and potentially anywhere else in the body.
What viruses are used in virotherapy?
Clinical Development Most of the work has been done on herpesvirus, adenovirus, and vaccinia virus, but other viruses include measles virus, coxsackievirus, polio virus, newcastle disease virus, and more. Methods of delivery tested include intratumoral, intravenous, intraperitoneal, and more.
What are the potential risks of oncolytic virus therapy?
Common side effects associated with the currently approved oncolytic virus may include but are not limited to: chills, fatigue, flu-like symptoms, injection site pain, nausea, and fever.
What is one difficulty with using oncolytic viruses to combat tumors?
Currently, the two most challenging problems of oncolytic virotherapy are as follows: (i) to ensure that the virus can maximize the ability of invasion and replication in tumor cells without infecting healthy tissues and cells to minimize the damage to the body and (ii) to prevent the virus from being eliminated by the …
How successful is immunotherapy for metastatic melanoma?
In a small study published in the Journal of Clinical Oncology, scientists reported a 3-year overall survival rate of 63 percent among 94 patients treated with this combination of drugs. All of the patients had stage 3 or stage 4 melanoma that couldn’t be removed with surgery.
How are oncolytic viruses administered?
(a) Intravenous delivery: When oncolytic viruses are injected into the peripheral vein, they reach tumor lesions in non-specific organs and systems through the circulation system. (b) Intratumoral delivery: When oncolytic viruses are injected into tumors, they have a direct therapeutic effect on the lesion.
Is virotherapy safe?
Since then, in pace with the success of tumor immunotherapy, scientists have paid more attention to oncolytic virotherapy. There is growing recognition that oncolytic virotherapy has the potential to be a safe treatment for cancer patients.
How does oncolytic virus therapy treatment work?
D. Oncolytic viruses are a form of immunotherapy that uses viruses to infect and destroy cancer cells. Viruses are particles that infect or enter our cells and then use the cell’s genetic machinery to make copies of themselves and subsequently spread to surrounding uninfected cells.
What are the benefits of oncolytic virus therapy?
T-VEC, an oncolytic virus, works by infecting and killing tumor cells, like these dividing melanoma cells, and stimulating an immune response against cancer cells throughout the body.
How is virotherapy different from chemotherapy?
The goal of virotherapy, not unlike that of radiation therapy and chemotherapy, is to destroy cancer cells, but virotherapy has several distinct advantages: Virotherapy destroys tumour cells selectively without affecting the healthy cells of the body.
What are the risks of oncolytic virus therapy?
Does T-Vec kill melanoma cells?
Oncolytic Virus Therapy Shows Benefit in Patients with Melanoma. July 21, 2015, by NCI Staff. T-VEC, an oncolytic virus, works by infecting and killing tumor cells, like these dividing melanoma cells, and stimulating an immune response against cancer cells throughout the body.
Can a virus-based immunotherapy improve response rate in melanoma?
In a phase III clinical trial, an investigational virus-based immunotherapy, talimogene laherparepvec (T-VEC), significantly increased the durable response rate in patients with metastatic melanoma compared with granulocyte-macrophage colony-stimulating factor (GM-CSF).
How often do you give T VEC for melanoma?
Oncolytic Virus Therapy Shows Benefit in Patients with Melanoma. T-VEC was injected directly into the tumors, and subsequent doses were administered 3 weeks after the first dose, then once every 2 weeks. GM-CSF was administered subcutaneously every day for 14 days, in 28-day cycles.